Neuralink, the neurotechnology company founded by Elon Musk, has announced its intention to commence human trials for its vision restoration chip. This implantable device aims to bypass damaged optical nerves and directly stimulate the visual cortex of the brain, potentially restoring sight to individuals with blindness caused by optic nerve damage or retinal disease. The company has previously conducted trials on animals, demonstrating the feasibility of its brain-computer interface technology.
The prospect of restoring vision through direct neural stimulation represents a significant advancement in treating blindness. Current therapeutic options are limited for many forms of vision loss, particularly those involving nerve damage. Successful human trials for Neuralink's device could offer a new pathway for individuals who have no other recourse, marking a pivotal moment in the intersection of artificial intelligence, neuroscience, and medical technology.
“Musk Says Neuralink to Begin Human Trials of Vision Chip”
Khaama Press
The Musk Wire aggregates and deduplicates public feeds; it does not republish articles. Continue to news.google.com to read the reporting in full.